MSD’s investigational two-drug HIV combination has been proven safe, efficacious and non-inferior to current standard of care ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...

Merck's new oral HIV-1 treatment shows positive results for adults, with stable weight, metabolic health, and safety. Read ...

In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies ...

Human Immunodeficiency Virus (HIV) is a retrovirus which is capable of causing AIDS (Acquired Immuno Deficiency Syndrome). HIV weakens the body’s immune system resulting in infections and ...

Medication errors during hospitalization and during care transitions are common for patients living with HIV and others who receive antiretrovirals, and these errors can cause adverse effects and ...

Some studies suggest that combination antiretroviral therapy in pregnant women with human immunodeficiency virus type 1 (HIV-1) infection increases the risk of premature birth and other adverse ...

What Are HIV/AIDS Medications? HIV medications can help lower your viral load, fight infections, and improve your quality of life. They can lower your chances of spreading HIV, but if you take them ...

The inclusion of lamivudine (3TC) in first-line tenofovir-based regimens with commonly used non-nucleoside reverse transcriptase inhibitors is associated with a greater risk for virologic failure than ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...